Loading
FPI-2265 is an experimental radioligand therapy from Fusion Pharmaceuticals in phase 2 trials for prostate cancer, aimed at PSMA.
FPI-2265 is a radioligand therapy developed by Fusion Pharmaceuticals. Its target is PSMA (the sponsor names PSMA). The sponsor states: A PSMA-targeting ligand (PSMA-I&T) radiolabeled with the alpha-emitter actinium-225, delivering targeted alpha radiotherapy to PSMA-positive prostate cancer cells. ClinicalTrials.gov describes the intervention as: Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in prostate cancer. The largest, NCT05219500, plans to enrol 115 participants with primary completion was scheduled for 2025-05-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A PSMA-targeting ligand (PSMA-I&T) radiolabeled with the alpha-emitter actinium-225, delivering targeted alpha radiotherapy to PSMA-positive prostate cancer cells. Connects to PSMA.
1.FPI-2265 binds PSMA on the cancer cell or is taken up by it.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FPI-2265" OR ABSTRACT:"FPI-2265" OR TITLE:"Ac225-PSMA I&T" OR ABSTRACT:"Ac225-PSMA I&T") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FPI-2265, not a curated reading list.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares PSMA, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer, AstraZeneca and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares AstraZeneca, Prostate cancer and the tag pipeline.